AI Article Synopsis
- Heterologous boost regimens involving an mRNA vaccine after a DNA vaccine are gaining interest for enhancing immunity against SARS-CoV-2.
- In a clinical trial with 32 participants, those who received an mRNA vaccine 6 to 8 months after the GLS-5310 DNA vaccine reported no adverse events, indicating a good safety profile.
- The study found significant improvements in immune responses, with increased antibody and T-cell levels, marking it as the first report on immune responses from this specific vaccination strategy.
Article Abstract
Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112-120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two-dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242151 | PMC |
| http://dx.doi.org/10.1016/j.vaccine.2023.06.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!